Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics Inc. (CORT)
NASDAQ:CORT
Corcept Therapeutics (CORT) Stock Price & Analysis
672 Followers
CORT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$20.84 - $35.22
Previous Close$33.88
Volume811.32K
Average Volume (3M)1.13M
Market Cap
$3.53B
Enterprise Value$3.16B
Total Cash (Recent Filing)$368.22M
Total Debt (Recent Filing)$151.00K
Price to Earnings (P/E)31.9
Beta0.54
Next Earnings
Jul 31, 2024EPS Estimate
$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.06
Shares Outstanding104,112,088
10 Day Avg. Volume1,398,734
30 Day Avg. Volume1,130,090
Standard Deviation0.14
R-Squared0.03
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)6.17
Price to Sales (P/S)6.48
Price to Cash Flow (P/CF)132.80
P/FCF Ratio132.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.55
Enterprise Value/Gross Profit6.64
Enterprise Value/Ebitda25.94
Forecast
1Y Price Target
$45.88Price Target Upside32.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Corcept Therapeutics News
Bulls Say, Bears Say
Bulls Say
EarningsSales of Korlym remain strong, and the company appears on track to achieve its revenue guidance.
Product ApprovalRelacorilant achieved, with statistical significance, both major endpoints in the study.
Regulatory PathThe regulatory path for relacorilant in Cushing’s is clear, with a high probability of receiving FDA approval, given that the study met its primary endpoint.
Bears Say
Clinical TrialsThere remains clinical risk on the overall outcome of the GRACE trial, as well as the regulatory and commercial future associated with it.
Legal IssuesTEVA filed a lawsuit against CORT claiming Korlym's orphan pricing is egregious and that some of CORT's patents are invalid.
Sales PracticesTEVA's accusations of doctor kickbacks is essentially a re-hash of the ongoing NJ USAO's investigations into CORT's sales practices.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CORT FAQ
What was Corcept Therapeutics Inc.’s price range in the past 12 months?
Corcept Therapeutics Inc. lowest stock price was $20.84 and its highest was $35.22 in the past 12 months.
What is Corcept Therapeutics Inc.’s market cap?
Currently, no data Available
When is Corcept Therapeutics Inc.’s upcoming earnings report date?
Corcept Therapeutics Inc.’s upcoming earnings report date is Jul 31, 2024 which is in 8 days.
How were Corcept Therapeutics Inc.’s earnings last quarter?
Corcept Therapeutics Inc. released its earnings results on May 01, 2024. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.03.
Is Corcept Therapeutics Inc. overvalued?
According to Wall Street analysts Corcept Therapeutics Inc.’s price is currently Undervalued.
Does Corcept Therapeutics Inc. pay dividends?
Corcept Therapeutics Inc. does not currently pay dividends.
What is Corcept Therapeutics Inc.’s EPS estimate?
Corcept Therapeutics Inc.’s EPS estimate is $0.23.
How many shares outstanding does Corcept Therapeutics Inc. have?
Corcept Therapeutics Inc. has 104,112,090 shares outstanding.
What happened to Corcept Therapeutics Inc.’s price movement after its last earnings report?
Corcept Therapeutics Inc. reported an EPS of $0.25 in its last earnings report, beating expectations of $0.22. Following the earnings report the stock price went up 4.941%.
Which hedge fund is a major shareholder of Corcept Therapeutics Inc.?
Among the largest hedge funds holding Corcept Therapeutics Inc.’s share is Royce & Associates LLC. It holds Corcept Therapeutics Inc.’s shares valued at 8M.
---
Corcept Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.88 (32.72% Upside)
$45.88 (32.72% Upside)
Blogger Sentiment
Bullish
CORT Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 49.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 22.4%
Last 30 Days ▲ 22.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.85%
12-Months-Change
Fundamentals
Return on Equity
21.75%
Trailing 12-Months
Asset Growth
6.16%
Trailing 12-Months
Company Description
Corcept Therapeutics Inc.
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
---
CORT Earnings Call
Q1 2024
0:00 / 0:00
---
CORT Stock 12 Month Forecast
Average Price Target
$45.88
▲(32.72% Upside)
Technical Analysis
Best Analysts Covering CORT
1 Year
1 Year Success Rate
11/12 ratings generated profit
1 Year Average Return
+16.89%
reiterated a buy rating last month
Copying Edward Nash's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +16.89% per trade.
---